Clinical Prevalence and Treatment Standards for Nonalcoholic Fatty Liver Disease Among Diabetic Patients in India - A Physicians’ Survey

  • Usha Rathi, Vinodraj Kundapur
Keywords: Type 2 diabetes mellitus, nonalcoholic fatty liver disease, India, prevalence, management

Abstract

Background/Aims: Type 2 diabetes mellitus (T2DM), obesity, and hyperinsulinemia are predisposing factors for nonalcoholic
fatty liver disease (NAFLD). The prevalence of NAFLD in Indian subjects with T2DM is reported to range from 12.5% to 87.5%, with studies over the years showing an increasing trend. This study aimed to understand the prevalence patterns, gaps in management, and current treatment options for the management of NAFLD in Indian patients with T2DM.
Methods: A 15-question survey form was used to assess physicians’ practice, and attitudes regarding NAFLD in diabetic patients. Each physician provided data for 15 patients with T2DM and underlying NAFLD who were receiving treatment for
NAFLD.
Results: In all, 271 physicians from 93 cities responded to the survey. According to 80% of the physicians, NAFLD was prevalent in 40%-60% of patients with T2DM. Diabetes with obesity, hypertension, and dyslipidemia was reported to affect the severity of NAFLD in patients with T2DM. Most patients with T2DM and NAFLD were aged 40-60 years, and 94.5% of physicians responded that their glycated hemoglobin (HbA1c) was >7%. Only 36.5% of the physicians reported screening 40%-60% of patients with T2DM for NAFLD, with liver function tests (LFTs) and ultrasonography being the most common approach used by 78.6% of the physicians. Abnormal LFTs and fatty liver on ultrasonography were the criteria for initiating drug therapy. Lifestyle modifications with drug therapy were the most common approach for management, and ursodeoxycholic acid and vitamin E were the main drugs of choice. Only 33.9% of the physicians used LFTs every three months for follow-up of patients with NAFLD.
Conclusion: Although NAFLD was observed in 40%-60% of subjects with T2DM, especially those aged 40-60 years, the percentage of patients screened, treated, and followed-up for NAFLD in routine clinical practice continues to remain low.
Conflict of Interest: Usha Rathi has no conflicts of interest to declare. Vinod Kundapur is an employee of Abbott
Source of Support: This study was funded by Abbott India Limited, Mumbai, India.

References

1. Ludwig J, Viggiano T, McGill D, Ott B. Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.
2. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65:1096–108.
3. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-18.
Published
2021-10-04
How to Cite
Usha Rathi, Vinodraj Kundapur. (2021). Clinical Prevalence and Treatment Standards for Nonalcoholic Fatty Liver Disease Among Diabetic Patients in India - A Physicians’ Survey. The Indian Practitioner, 74(9), 19-26. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/1243